Introduction {#s1}
============

Atrial fibrillation (AF), the most common cardiac arrhythmia encountered in clinical practice, represents a growing clinical and economic burden.^[@EUT001C1]^ Atrial fibrillation is considered an epidemic, affecting 1 to 1.5% of the population in the developed world, and is projected to grow at least three-fold by 2050.^[@EUT001C2]^ The prevalence of AF is markedly increasing in our ageing society. The Rotterdam study, a large, European, population-based study, reported an overall prevalence of 5.5%, with age-specific prevalence ranging from 0.7% of people aged 50--59 years to 17.8% of those aged 85 years and older.^[@EUT001C3]^ Strongly associated with increased risk of mortality and morbidity due to stroke and other vascular complications, AF is a major public health burden.^[@EUT001C4]^

Although many clinical trials have shown that anticoagulation with warfarin and other vitamin K antagonists (VKAs) decreases the risk of ischaemic stroke in patients with AF, concerns remain regarding their long-term safety, mainly increased risk of bleeding, and prescribing practices for VKAs. Warfarin therapy is complicated because of the wide inter-individual variation in response and dose requirements for adequate anticoagulation, narrow therapeutic range \[international normalized ratio (INR), 2.0--3.0 for AF\], need for chronic anticoagulation monitoring, potentially life-threatening interaction with numerous foods and drugs, and long onset and offset of action. These factors all contribute to the significant underuse of warfarin in patients with AF at risk for stroke despite clear indication for its use.^[@EUT001C5],[@EUT001C6]^ Vitamin K antagonists are also one of the drug classes creating the highest rates of emergency admissions to the hospital in the elderly.^[@EUT001C7]^

A number of published studies have reported risk of bleeding and mortality associated with warfarin and other VKAs; however, no systematic review has been performed to date to collate the available evidence. Thus, this study systematically assembled the best evidence from randomized clinical trials (RCTs) and observational studies conducted in the real-life setting to evaluate the risk of bleeding and mortality in the population with AF treated with warfarin and other VKAs.

Methods {#s2}
=======

Literature search and data extraction {#s2a}
-------------------------------------

This review was performed systematically in an unbiased manner by using a pre-specified protocol and an explicit, reproducible plan for literature search and synthesis. Study designs such as RCTs, prospective cohort studies, and retrospective study designs were included in this review. Searches to identify RCTs were of literature published from 1960 to 7 March 2012; searches to identify observational studies were of literature published from January 1990 to 7 March 2012, as observational clinical data published before 1990 are unlikely to be relevant to current treatment practices and resource patterns. No limitations on publication language or geographical perspective were applied. Translation of the articles to English was done as required.

The following electronic databases were searched: MEDLINE, EMBASE, BIOSIS, and the Cochrane Library. In addition, conference abstracts from 2010 to March 2012 from the American Heart Association, International Society on Thrombosis and Haemostasis, and European Society of Cardiology were searched. Search terms included combinations of free text and medical subject headings. Separate sets of terms were used for the health condition of interest (AF), the treatment of interest (VKAs), and the study types of interest (RCTs and observational studies). The specific search strategies for MEDLINE are shown in Appendix 1. Study inclusion was performed at two levels in parallel by two researchers. At level 1, titles and abstracts of all identified articles were screened. Articles were excluded if their abstracts fit any of the pre-specified exclusion criteria: case reports, letters, comments, editorials, and reviews. The full text of all papers determined to be eligible at level 1 was reviewed at level 2 to ensure that they met the inclusion criteria. All disagreements at various stages were resolved by consensus with input from an experienced senior researcher.

For each eligible study that passed both levels of screening, data were extracted by one researcher and verified with the original sources by a second researcher. To focus the review on large, comprehensive studies, only studies that included 300 or more patients receiving VKA treatment were selected. This sample size cut-off point was chosen so that, in the absence of an event, the upper limit of the 95% confidence interval (CI) for the event would be 1%, according to Hanley\'s rule.^[@EUT001C8]^

Data synthesis {#s2b}
--------------

Results of this systematic literature search were mainly summarized qualitatively using descriptive statistics. Qualitative synthesis consisted of detailed evidence tables and figures that included information on the study design, population size and characteristics (INR target range, percentage of time in INR range, CHADS2 criteria, and prescribing information), and results (i.e. mortality and bleeding in AF). Some data imputations were necessary to derive number of events, total patient-years, and rates per 100 patient-years. If not directly reported, patient-years for the group were calculated from the sum of the length of follow-up for each participant. When only two of these three estimates (number of events, total patient-years, and rate) were reported, the third was imputed using simple calculations. Univariate summaries, including the median, interquartile range (IQR), and weighted mean (weighted by sample size), were produced and are presented in a box-and-whisker plot.

This review assessed a potentially optimized VKA usage within the last two decades that might have impacted the incidence of bleeding and mortality. To assess this, we used a weighted linear regression model. For RCTs, the publication year was used, while for observational studies the midpoint of the observed period was taken, as these studies included data over a longer time period. Where observational studies did not give the start and end dates of the observation period, we imputed these dates from the year of publication and the average follow-up for patients.

Results {#s3}
=======

Study identification and characteristics {#s3a}
----------------------------------------

A total of 3286 records were retrieved after the searches were performed, and 47 studies with a sample size of at least 300 patients were included in the review. Of the included studies, 16 were RCTs and 31 were observational studies with either a prospective or retrospective study design. The search results are summarized in *Figure [1](#EUT001F1){ref-type="fig"}*, PRISMA flowchart. Detailed summaries of the included studies are provided in Appendices 2 and 3. Figure 1Flow chart for study inclusion and exclusion. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-analyses; RCTs, randomized controlled trials.

### Randomized controlled trials {#s3a1}

All included RCTs were active-controlled trials that were published from 1989 through 2011 and designed to compare newer drugs with VKAs. Their primary objective was to evaluate frequency of fatal and non-fatal stroke (ischaemic or haemorrhagic), intracranial haemorrhage, or other clinically significant arterial embolism in patients who were treated with dose-adjusted VKA. The sample size in the warfarin treatment arm ranged from 319 to 9081 and the cumulative patient-years were 61 563. In all studies, the mean age of patients was greater than 60 years (range, 63--82 years) and most had a majority of male patients (range, 49 to 70%). Study length ranged from 5 months to 3 years. Among patients in the VKA group, the proportion of time in which the intensity of anticoagulation was in the therapeutic range calculated from all INR values during the study ranged from 42 to 86%.^[@EUT001C9],[@EUT001C10]^ In most RCTs, the target therapeutic INR range of 2.0--3.0 was used, with the exception of four studies. In one study, warfarin dosage was adjusted to achieve an INR range of 1.7--3.0;^[@EUT001C11]^ whereas in three other studies, warfarin dosage was adjusted to achieve an INR range of 2--4.5.^[@EUT001C9],[@EUT001C10],[@EUT001C12]^

### Observational studies {#s3a2}

All 31 observational studies were published during the years 2001 to 2011. Data sources for these studies included registries, claims databases, hospital and anticoagulation clinic electronic records (inpatient and outpatient), and national mortality statistics databases. The year midpoint during which the data were collected for these studies was from 1997 to 2009. Most of the published studies were from data sources in the USA; other countries included the UK, Italy, Sweden, Denmark, Norway, Japan, Hong Kong (China), Australia, and Israel. The sample size in these studies ranged from 328 to 70 057 and the cumulative patient-years was 484 241. The included studies had a mean age range of 64--83 years and a greater proportion of male patients (\>50%).

### Bleeding {#s3a3}

All randomized trials provided a definition for major bleeding, which was consistent across most trials (*Table [1](#EUT001TB1){ref-type="table"}*). The most frequent definition for major bleeding was bleeding that was fatal or overt bleeding with a drop in haemoglobin level of at least 20 g/L or requiring transfusion of at least 2 units packed blood cells, or haemorrhage into a critical anatomical site (e.g. intracranial, retroperitoneal). The overall median incidence of major bleeding in the included RCTs was 2.1 per 100 patient-years (range, 0.9--3.4 per 100 patient-years; IQR, 1.5--3.1 per 100 patient-years) (*Figure [2](#EUT001F2){ref-type="fig"}*), and the weighted mean was 2.8 per 100 patient-years. Table 1Major bleeding data---RCTsPrimary author (trial name)Publication yearPatients with ≥1 major bleedPatients (*N*)Rate per 100 patient-yearsDefinition of major bleedingAlbers (SPORTIF V) ^[@EUT001C13]^20058419623.1Bleeding that was fatal or clinically overt and associated with either transfusion of ≥2 units of blood or a decrease in Hb ≥ 20 g/L, or bleeding that was intracranial, retroperitoneal, spinal, ocular, pericardial, or atraumatic articular (intracranial bleeding excludes intracerebral haemorrhages, which were counted as primary events)Bousser (AMADEUS)^[@EUT001C14]^20082922931.4Bleeding that was fatal, intracranial, or affected another critical anatomical site, or overt bleeding with a drop in Hb ≥20 g/L or requiring transfusion of ≥2 units of erythrocytesChen (NA)^[@EUT001C11]^2009236591.2Cerebral or gastric haemorrhageConnolly (ACTIVE W)^[@EUT001C15]^20069333712.2Any bleeding requiring transfusion of ≥2 units of RBCs or equivalent of whole blood, or which was severe. Severe bleeding associated with any of the following: death, drop in Hb of ≥50 g/L, substantial hypotension with the need for inotropic agents, intraocular bleeding leading to substantial loss of vision, bleeding requiring surgical intervention (other than vascular site repair), symptomatic intracranial haemorrhage, or requirement for a transfusion of ≥4 units of bloodConnolly (RE-LY)^[@EUT001C16]^200942160223.4A reduction Hb of ≥20 g/L, transfusion of ≥2 units of blood, or symptomatic bleeding in a critical area or organ. Life-threatening bleeding was a subcategory of major bleeding that consisted of fatal bleeding, symptomatic intracranial bleeding, bleeding with a decrease in the Hb level of at least 50 g/L, or bleeding requiring transfusion of ≥4 units of blood or inotropic agents or necessitating surgeryGranger (ARISTOTLE)^[@EUT001C17]^201146290523.1Major bleeding was defined according to the ISTH criteria: clinically overt bleeding accompanied by a decrease in the Hb level of ≥2 g/dL or transfusion of ≥2 units of packed red cells, occurring at a critical site, or resulting in deathLip (NCT00684307)^[@EUT001C18]^200923181.4Fatal bleeding, clinically overt bleeding causing a fall in Hb level of ≥20 g/L (1.24 mmol/L) or leading to transfusion of ≥2 units of whole blood or red cells, bleeding in areas of special concern or bleeding causing permanent treatment cessation; safety analysis populationMant (BAFTA)^[@EUT001C19]^2007254881.9Major haemorrhages were intracranial, haemorrhagic stroke or major extracranial haemorrhage (defined as a fatal haemorrhage or one that resulted in the need for transfusion or surgery), other admissions to hospital for haemorrhage, hospital admission or death as a result of a non-stroke vascular event, and all-cause mortalitySPAF Investigators (SPAF II)^[@EUT001C10]^1994345553.1Major haemorrhage was assessed by the criteria of Landefeld *et al.*^[@EUT001C20]^SPAF Investigators (SPAF III)^[@EUT001C21]^1996125232.1A bleeding event was called major when it involved the central nervous system; required hospitalization, blood transfusion, and/or surgical intervention; or resulted in permanent functional impairment to any degree. All intracranial haemorrhages were confirmed by neuroimaging. Major haemorrhage was assessed by the criteria of Landefeld *et al.*^[@EUT001C20]^Morocutti (SIFA)^[@EUT001C12]^199744540.9Non-cerebral and non-fatal bleeding events were classified as major if they were severe, i.e. they made it necessary to hospitalize the patient, administer a blood transfusion, or perform surgeryOlsson (SPORTIF III)^[@EUT001C22]^20034117031.8Major bleeding included fatal bleeding; clinically overt bleeding associated with a reduction in Hb ≥ 20 g/L; clinically overt blood loss needing transfusion of ≥2 units of whole blood or erythrocytes; bleeding involving critical anatomical sites (intracranial, intraspinal, intraocular, retroperitoneal, pericardial, or atraumatic intra-articular haemorrhage)Pérez-Gómez (NASPEAF)^[@EUT001C23]^2004234792.0Severe bleeding (bleeding was considered severe when requiring hospital admission, blood transfusion, or surgery)Patel (ROCKET-AF)^[@EUT001C24]^201138671253.4Major bleeding was defined by any of the following: a fatal outcome; involvement of a critical site (i.e. intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, or retroperitoneal bleeding); or clinically overt (≥2 g/dL fall in Hb, or requiring the transfusion of ≥2 units of packed RBCs or whole blood)[^1][^2] Figure 2Box-and-whisker plot to summarize major bleeding rates per 100 Patient-years. RCTs, randomized controlled trials. The shaded boxes display the range of the 25th and 75th percentiles (IQR); the dashed line is the median value. The 'whiskers' (lines with horizontal caps) indicate the range of values within 1.5 times the IQR outside the IQR, and the circles indicate data points that fall outside the range of the whiskers, i.e. potential outliers. The weighted mean rates per 100 patient-years were 2.8 for major bleeding in RCTs and 4.4 for major bleeding in observational studies.

In observational studies, the definition of major bleeding varied across studies (*Table [2](#EUT001TB2){ref-type="table"}*). Some studies focused mainly on gastrointestinal bleeding,^[@EUT001C30],[@EUT001C35],[@EUT001C46],[@EUT001C51],[@EUT001C52]^ whereas other studies included patients that had bleeding from other anatomical sites. The incidence of major bleeding in the observational studies was similar to that in the RCTs---median 2.0 per 100 patient-years (range, 0.2--7.6 per 100 patient-years; IQR, 1.5--3.8 per 100 patient-years); weighted mean, 4.4 per 100 patient-years---but variation was greater in the observational studies (*Figure [2](#EUT001F2){ref-type="fig"}*). Table 2Major bleeding data---observational studiesPrimary authorPublication year (midpoint of follow-up)Patients, (*N*)Major bleeding events (*n*)Total patient-yearsRate per 100 patient-yearsDefinition of major bleedingAbdelhafiz^[@EUT001C26]^2004 (2001)402116341.74Major bleeding complications were defined as bleeding that led to hospital admission, emergency procedure, and/or blood transfusionBlich^[@EUT001C27]^2004 (1999)506511228.54.15NRBosch^[@EUT001C28]^2002 (1998)128311946722.55Major haemorrhage in hospital settingBoulanger^[@EUT001C29]^2006 (2000)256810336652.81Bleeding events included intracranial or GI haemorrhage and other bleeding episodes (e.g. haemopericardium, haematuria, haemarthrosis, epistaxis and haemoptysis)Cheung^[@EUT001C30]^2005 (2001)55588930.90GI bleedsCopland^[@EUT001C31]^2001 (1999)32894581.97Haemorrhages leading to fall in Hb level 2 g/L or transfusion (intracerebral and subdural not included)Currie^[@EUT001C32]^2005 (1999)15136885000.80NRDarkow^[@EUT001C33]^2005 (2001)4895NRNR2.68A haemorrhagic event was defined as acute inpatient hospitalization with a primary diagnosis of intracranial haemorrhage or other major bleedingFang^[@EUT001C34]^2007 (1997)13 5599815 3700.64Bleeding was defined as major extracranial haemorrhage, fatal, requiring transfusion of ≥2 units of packed red blood cells, or haemorrhage into a critical anatomical site, such as the retroperitoneum. To restrict analyses to the most serious haemorrhages, events not leading to hospitalization or death were excludedGhate^[@EUT001C35]^2011 (2005)37 75653121 4232.48Major GI bleeding events were defined as GI bleeding that required hospitalization, identified based on inpatient claims associated with an ICD-9 code for GI bleedingHansen^[@EUT001C36]^2010 (2002)50 919364293 4923.90Bleeding was defined as admission to a Danish hospital, excluding emergency department visits, with a bleeding diagnosis (primary or secondary and classed as airway, intracranial, GI, urinary tract), a non-fatal bleeding episode, or a diagnosis of bleeding as the cause of death reported in the National Causes of Death Register (i.e. a fatal bleeding episode).Ho^[@EUT001C37]^2011 (2004)476331 9411.70Major bleeding was defined as intracranial bleeding, subarachnoid haemorrhage, subdural haematoma, haemorrhagic transformation of a primary ischaemic stroke (as documented by computed tomography scan, magnetic resonance imaging or autopsy) or any bleeding leading to transfusion of ≥2 units of whole blood or erythrocytes or bleeding requiring surgical or angiographic intervention, or bleeding resulting in permanent disability or involving a critical anatomical siteHylek^[@EUT001C38]^2007 (2002)472263607.22Major haemorrhage was defined as bleeding that was fatal, required hospitalization with transfusion of \>2 units of packed RBCs, or involved a critical site (i.e. intracranial, retroperitoneal, intraspinal, intraocular, pericardial, or atraumatic intra-articular haemorrhage)Jackson^[@EUT001C39]^2001 (1998)5059267.73.40Bleeding complications were considered major if these involved intracranial or intracerebral haemorrhage, were life-threatening, or required blood transfusionMercaldi^[@EUT001C40]^2011 (2005)70 05712 039158 4087.60Major bleeding events included extracranial haemorrhages resulting in hospitalization or an emergency room visitNaganuma^[@EUT001C41]^2012 (2004)8452819001.47Major bleeding events were defined as intraocular haemorrhages leading to a substantial loss of vision, GI haemorrhage or other severe haemorrhage that was fatal or required endoscopic haemostasis, surgical intervention, hospital admission, or blood transfusionNichol^[@EUT001C42]^2008 (2003)11078420834.00The first diagnosis for a bleed resulting in hospitalization occurring 30 or more days after the index date was classified as an event (ICD-9 codes)Njaastad^[@EUT001C43]^2006 (1999)4214475.20.84Bleeding was defined as major if it was associated with at least one of the following: death; intracranial, retroperitoneal, intraocular, or intra-articular bleeding; a decrease in haemoglobin level ≥20 g/L; need for transfusion of ≥2 units of blood; or need for surgical or medical interventionOlesen^[@EUT001C44]^2011 (2003)37 4255183133 6143.88Bleeding included GI bleeding, intracranial bleeding, bleeding from the urinary tract, and airway bleedingPengo^[@EUT001C45]^2001 (1999)433116151.79The following were considered to be major bleeding events: fatal (death due to haemorrhage); intracranial (documented by CAT and/or NMR); ocular (with blindness); articular; retroperitoneal; bleeding requiring surgery or angiographic intervention to stop bleeding; bleeding leading to haemoglobin reduction of ≥2 g/dL and/or need for transfusion of ≥2 blood unitsPoli^[@EUT001C46]^2005 (2002)36428590.23GI bleedsPoli^[@EUT001C47]^2009 (2003)7833725671.44Bleeding was classified as major when fatal, intracranial (documented by imaging), ocular causing blindness, articular, or retroperitoneal; when surgery or transfusion of \>2 blood units were required or when haemoglobin was reduced by ≥2 g/dLPoli^[@EUT001C48]^2011 (2009)30159076301.18Major endpoints of the study were first major bleeding, defined fatal, ocular causing blindness, articular, or retroperitoneal bleeding; when surgery or an invasive manoeuvre was necessary to stop bleeding; when transfusion of \>2 units of blood was required; or when Hb was reduced by \>2 g/dL.Poli^[@EUT001C49]^2011 (2008)33029710 0190.97Bleeding was classified as 'major' when it was fatal, intracranial (documented by imaging), ocular causing blindness, articular, or retroperitoneal; when surgery or transfusion of \>2 blood units was required; or when Hb was reduced by \>2 g/dL.Rose^[@EUT001C50]^2008 (2001)3396552892.11.90Major haemorrhage was defined according to the ISTH definition: a fatal event, an event requiring hospitalization with transfusion of at least 2 units of packed red blood cells, or bleeding involving a critical anatomical site such as the cranium or the retroperitoneumRosenman^[@EUT001C51]^2009 (2003)148512733643.80GI bleedsShireman^[@EUT001C52]^2004 (1999)81319820044.89Major bleeds included GI haemorrhages that resulted in an inpatient admission. Only the first episode of a major bleed per cohort member during the study period was included. Number of major bleeds and patient-years were imputed from the *N* and %, which in turn enabled rate per 100 patient-years to be imputedSuzuki^[@EUT001C53]^2007 (2005)66795031.79Major bleeding was defined as bleeding that required emergent hospitalization and included extracranial haemorrhages (GI haemorrhages, haematuria, haemoptysis)Wess^[@EUT001C54]^2008 (2000)501528765.94All GI bleeds and intracranial haemorrhages based on ICD-9-CM codes recorded on inpatient hospitalization claimsWieloch^[@EUT001C55]^2011 (2008)24915320432.59ISTH guidelines include central nervous system, GI, and other bleedsYousef^[@EUT001C56]^2004 (1999)7392814841.89Any bleeding event leading to hospitalization[^3]

Regression models (weighted) were used to examine the relationship between potentially optimized VKA usage over time and major bleeding, and results showed that bleeding rates or bleeding reporting tended to increase over the last decade in both RCTs and observational studies; the increase was statistically significant in observational studies (*Figure [3](#EUT001F3){ref-type="fig"}*). The regression model estimates the increase in major bleeding rate over a period of 10 years to be 3.84 per 100 patient-years (95% CI, 0.68 to 7.00, *P* = 0.019), for observational studies and 1.00 per 100 patient-years (95% CI, −0.05 to 2.05, *P* = 0.061) for RCTs. Although some observations on the scatter plots lie outside the CIs, these may have minimal impact on the fitted regression if the sample sizes are relatively small, as these are weighted regressions. Figure 3Weighted regression of major bleeding rates in RCTs and observational studies. Obs, observational studies; RCTs, randomized controlled trials. This figure presents the rates of major bleeding observed by year of study. The shaded areas indicate 95% CIs of the fitted regression line.

### Mortality {#s3a4}

In most clinical studies, mortality was evaluated as a secondary endpoint and was commonly defined as death due to vascular diseases or all-cause mortality. Of the 16 RCTs, 15 reported all-cause mortality and 11 reported vascular mortality, of which 10 reported both all-cause and vascular mortality; data are presented in *Table [3](#EUT001TB3){ref-type="table"}*. To assess and compare all-cause and vascular mortality, summary data are presented for the 10 trials that report both. Median all-cause mortality in patients treated with VKAs was 4.5 per 100 patient-years (range, 2.9--8.0 per 100 patient-years; IQR, 3.8--5.8 per 100 patient-years) (*Figure [4](#EUT001F4){ref-type="fig"}*) and the weighted mean was 4.3 per 100 patient-years. Incidence of vascular mortality was 2.6 per 100 patient-years (range, 1.5--6.7 per 100 patient-years; IQR, 2.1 to 3.2 per 100 patient-years) (*Figure [4](#EUT001F4){ref-type="fig"}*) and the weighted mean was 2.3 per 100 patient-years. As a proportion of all-cause mortality, 52% (weighted mean) of deaths were classified as vascular (minimum, 31%; median, 62%; and maximum, 91%; *Table [3](#EUT001TB3){ref-type="table"}*). Although not investigated statistically, it is possible that the proportion of all deaths classified as vascular has reduced over time (*Figure [5](#EUT001F5){ref-type="fig"}*). In observational studies, all-cause mortality was reported in only 11 of 31 studies. Owing to heterogeneity in the methodology and the large differences in the reliability and validity of death reporting in the data sources (and hence in the reported mortality rates) and the relatively low proportion of included observational studies reporting mortality, we could not further summarize these data in a meaningful way. Table 3Mortality data---randomized controlled trialsAll-cause mortalityVascular mortalityPrimary author (trial name)Publication yearDeaths (*n*)Patients (*n*)Rate per 100 patient-yearsDeaths (*n*)Patients, (*n*)Rate per 100 patient-yearsPercentage of all-cause deaths that were vascularAlbers^[@EUT001C13]^200512319623.8NRNRNRNRBousser^[@EUT001C14]^20086122932.93322931.554.1Chen^[@EUT001C11]^2009106590.5NRNRNRNRConnolly^[@EUT001C15]^200615833713.810633712.567.1Connolly^[@EUT001C16]^200948760224.131760222.765.1Granger^[@EUT001C17]^201166990813.934390812.051.3Hu^[@EUT001C25]^200643350.8NRNRNRNRLip^[@EUT001C18]^200923181.4NRNRNRNRMant^[@EUT001C19]^20071074888.0414883.138.3Morocutti^[@EUT001C12]^1997324547.4294546.790.6Patel^[@EUT001C24]^201163270904.919370821.730.6Pérez-Gómez^[@EUT001C23]^2004434793.7284792.465.1Petersen^[@EUT001C9]^1989NRNRNR33350.5NRSPAF Investigators^[@EUT001C10]^1994625555.6365553.358.1SPAF Investigators^[@EUT001C21]^1996355235.9275234.677.1Olsson^[@EUT001C22]^20037917033.2NRNRNRNR[^4] Figure 4Box-and-whisker plot to summarize all-cause and vascular mortality rates per 100 patient-years. RCTs, randomized controlled trials. The shaded boxes display the range of the 25th and 75th percentiles (IQR); the dashed line is the median value. The 'whiskers' (lines with horizontal caps) indicate the range of values within 1.5 times the IQR outside the IQR, and the circles indicate data points that fall outside the range of the whiskers, i.e. potential outliers. The weighted mean rates per 100 patient-years were 4.3 for all-cause mortality and 2.3 for vascular mortality. Figure 5Weighted regression of mortality rates in RCTs by year. RCTs, randomized controlled trials. This figure presents the rates of mortality observed by year of reporting. The shaded areas indicate 95% CIs of the fitted regression line.

Within the RCT data, by using the publication year as a proxy to changing VKA management patterns over time, we found no clear evidence of a relationship with all-cause mortality, but some evidence of decreasing vascular mortality over time (*Figure [5](#EUT001F5){ref-type="fig"}*). Regression models (weighted) were used, and the models estimated a non-significant decrease in all-cause mortality rate over a period of 10 years to be −0.78 (95% CI, −2.66 to 1.09, *P* = 0.362) and a significant decrease in the vascular mortality rate over a period of 10 years to be −1.60 (95% CI, −2.77 to −0.44, *P* = 0.013).

Discussion {#s4}
==========

This systematic review of patients with AF confirms the assertion that there is a risk of major bleeding when treated with VKAs; this was confirmed by the overall incidence rates reported in RCTs and in observational studies conducted in the real-life clinical setting. The overall median rate of major bleeding was similar in the RCTs and the observational studies, but there was greater variation in the results reported in the observational studies. A sensitivity analysis performed in RCTs also including studies with smaller sample sizes (\<300) gave very similar results. The IQRs of major bleeding rates were similar in RCTs (1.5--3.1) and observational studies (1.5--3.8), suggesting that the observed increased variability in observational studies are in the extremes. The largest observed major bleeding rate in observational studies occurred in the largest study.^[@EUT001C40]^ Including this study from the US-Medicare claims database considerably increased the weighted mean bleeding rate from 3.1 to 4.4.

We critically examined some of the potential reasons for heterogeneity in the bleeding and mortality rates observed in the publications using the study year as a proxy to changing management patterns in clinical practice. Over the years, there has been greater awareness of the warfarin benefit-to-risk ratio, and there are efforts to stay within a narrow therapeutic range (INR, 2.0--3.0 for AF) by stringently monitoring anticoagulation parameters, and scrutinizing administration of co-medications and dietary products. Regression models (weighted) examined this relationship and results showed that bleeding rates tended to increase over time in both RCTs and observational studies; the increase was statistically significant in observational studies. A number of factors could all potentially contribute to this increase over time: changing definition of major bleeding over time; heightened awareness of major bleeding and therefore increased reporting; and changes in patterns of prescribing VKAs due to greater awareness of the positive benefit-to-risk ratio, leading to the more likely treatment of vulnerable patients that are at high risk of stroke, but also at risk of bleeding.

Other potential factors may include concurrent use of drugs that interact with VKAs, thereby increasing the risk of serious bleeding, which is a widespread problem in clinical practice. Many drugs interact with the metabolism of VKAs, and the number increases as new drugs enter the market. These drugs can lead to over-anticoagulation, under-anticoagulation, or increased bleeding risk by pathways independent of INR, such as altered platelet function. Enhanced sensitivity to oral anticoagulation with VKAs, resulting in a higher risk for bleeding that varies across patient populations, may be attributed to co-morbid conditions such as chronic renal failure,^[@EUT001C57]^ hepatic dysfunction, and old age. Not all studies have shown consistent results, making it difficult to get a clear view of the association of VKA use in real-life clinical settings with major bleeding and mortality.

The evidence gathered in this review suggests that there is a paucity of high-quality and consistently reported data for major bleeding. One of the limitations of this review is heterogeneity across the included observational studies in terms of patient population, study objectives, year of publication (which, for example, influences how VKA treatment is monitored), definitions of outcomes, and length of follow-up. In addition, quality of design and execution of observational studies can differ dramatically. These sources of heterogeneity are evident in the differences in the minimum and maximum major bleeding rates observed in the RCTs and observational studies. There was also lack of mortality data in observational studies. For studies that used claims database records, there is uncertainty about the accuracy and completeness of medical record documentation. Also, information of variables known to be associated with the risk of bleeding (such as specific co-morbidities^[@EUT001C58]^ or concomitant use of antiplatelets) was not reported sufficiently to incorporate them into our analyses.

Published after the cut-off date for the searches conducted for this study, a large (over 48 000 patients receiving VKAs only), well-conducted, high-quality observational study reported a major bleeding rate of 1.9 per 100 patient-years in patients treated with VKAs only over an observation period of 2005--2008.^[@EUT001C59]^ This finding is consistent with the median major bleeding rate observed across our included studies (2.0 per 100 patient-years). Another large observational study, published after the cut-off date, was in an AF cohort of 125 195 Canadian patients starting warfarin therapy.^[@EUT001C60]^ In this study the bleeding rate per 100 patient-years was 3.8, with major bleeding defined as a visit to an emergency department or an admission to hospital for haemorrhage during warfarin therapy. Bleeding rates were highest in the first 30 days of warfarin therapy (11.8 per 100 patient-years) compared with the remainder of the 5-year follow-up period (3.4 per 100 patient-years).

It could have been hypothesized that the bleeding rates in observational studies would be higher than those in RCTs, given that patients in RCTs are typically a more selective group than those receiving anticoagulation in routine care. In addition, it is widely known that VKA control in RCTs is systematically better than in routine care, probably relating to study investigators being more skilful in the handling of warfarin.^[@EUT001C61]^ That this did not lead to markedly different bleeding rates may be attributed to the fact that adverse event reporting in RCTs is typically more systematic and complete than in observational studies. Also, bleeding events can be prospectively defined and recorded in RCTs (often even with adjudication by an independent review board). Such consistent criteria are more difficult to apply in retrospective database studies.

The limitations of oral anticoagulation by VKAs, particularly safety concerns, have prompted the development and availability of new oral anticoagulants, such as the oral direct thrombin inhibitors (e.g. dabigatran etexilate) and oral factor Xa inhibitors (e.g. rivaroxaban and apixaban). These new drugs may cause less bleeding and do not require stringent monitoring like VKAs, and therefore may be useful alternatives to VKAs.
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[^1]: Two of the 16 included RCTs did not present major bleeding data; Petersen *et al.*^[@EUT001C9]^ and Hu *et al.*^[@EUT001C25]^.

[^2]: AF, atrial fibrillation; Hb, haemoglobin; ISTH, International Society on Thrombosis and Haemostasis; RBC, red blood cells; RCTs, randomized controlled trials.

[^3]: AF, atrial fibrillation; CAT, computed axial tomography; GI, gastrointestinal; Hb, haemoglobin; ICD-9-CM, International Classification of Diseases, 9th Revision, Clinical Modification; ISTH, International Society on Thrombosis and Haemostasis; NMR, nuclear magnetic resonance (imaging); NR, not reported; RBC, red blood cells.

[^4]: NR, not reported.
